BioMarin Pharmaceutical Inc.
BMRN
$55.61
$0.180.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.06B | 2.95B | 2.85B | 2.75B | 2.59B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.06B | 2.95B | 2.85B | 2.75B | 2.59B |
| Cost of Revenue | 946.28M | 949.13M | 969.01M | 970.80M | 910.38M |
| Gross Profit | 2.12B | 2.00B | 1.88B | 1.78B | 1.68B |
| SG&A Expenses | 905.12M | 935.87M | 955.66M | 958.41M | 964.22M |
| Depreciation & Amortization | 24.35M | 33.81M | 43.26M | 48.84M | 59.51M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.23B | 2.28B | 2.33B | 2.37B | 2.33B |
| Operating Income | 829.44M | 673.01M | 527.58M | 383.61M | 256.72M |
| Income Before Tax | 840.04M | 674.31M | 541.76M | 391.45M | 298.68M |
| Income Tax Expenses | 182.80M | 150.42M | 114.90M | 69.16M | 42.09M |
| Earnings from Continuing Operations | 657.24 | 523.88 | 426.86 | 322.29 | 256.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 657.24M | 523.88M | 426.86M | 322.29M | 256.59M |
| EBIT | 829.44M | 673.01M | 527.58M | 383.61M | 256.72M |
| EBITDA | 912.69M | 764.15M | 624.00M | 483.29M | 363.08M |
| EPS Basic | 3.44 | 2.75 | 2.25 | 1.70 | 1.36 |
| Normalized Basic EPS | 2.92 | 2.39 | 1.92 | 1.40 | 0.95 |
| EPS Diluted | 3.38 | 2.70 | 2.20 | 1.64 | 1.30 |
| Normalized Diluted EPS | 2.84 | 2.30 | 1.85 | 1.34 | 0.91 |
| Average Basic Shares Outstanding | 763.99M | 762.20M | 760.10M | 757.89M | 755.68M |
| Average Diluted Shares Outstanding | 787.29M | 790.71M | 793.50M | 788.75M | 782.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |